46 related articles for article (PubMed ID: 11255077)
1. Pharmacokinetics and biodistribution of a light-chain-shuffled CC49 single-chain Fv antibody construct.
Pavlinkova G; Colcher D; Booth BJ; Goel A; Batra SK
Cancer Immunol Immunother; 2000 Jul; 49(4-5):267-75. PubMed ID: 10941910
[TBL] [Abstract][Full Text] [Related]
2. Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.
Apgar JR; Mader M; Agostinelli R; Benard S; Bialek P; Johnson M; Gao Y; Krebs M; Owens J; Parris K; St Andre M; Svenson K; Morris C; Tchistiakova L
MAbs; 2016 Oct; 8(7):1302-1318. PubMed ID: 27625211
[TBL] [Abstract][Full Text] [Related]
3. Antibody engineering to generate anti-tumor-associated glycoprotein 72 mouse recombinant CC49 IgG with improved solubility, purity, and thermal stability.
Lin Z; Tu B; Hemken PM; Muerhoff AS
J Immunol Methods; 2024 Feb; 525():113606. PubMed ID: 38145790
[TBL] [Abstract][Full Text] [Related]
4. A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies.
Hsieh YC; Liao JM; Chuang KH; Ho KW; Hong ST; Liu HJ; Huang BC; Chen IJ; Liu YL; Wang JY; Tsai HL; Su YC; Wang YT; Cheng TL
J Nanobiotechnology; 2022 Jan; 20(1):58. PubMed ID: 35101043
[TBL] [Abstract][Full Text] [Related]
5. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.
De Groot AS; Terry F; Cousens L; Martin W
Expert Rev Clin Pharmacol; 2013 Nov; 6(6):651-62. PubMed ID: 24164613
[TBL] [Abstract][Full Text] [Related]
6. Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development.
Hicks D; Baehr C; Silva-Ortiz P; Khaimraj A; Luengas D; Hamid FA; Pravetoni M
Hum Vaccin Immunother; 2022 Nov; 18(6):2122507. PubMed ID: 36194773
[TBL] [Abstract][Full Text] [Related]
7. Computational optimization of antibody humanness and stability by systematic energy-based ranking.
Tennenhouse A; Khmelnitsky L; Khalaila R; Yeshaya N; Noronha A; Lindzen M; Makowski EK; Zaretsky I; Sirkis YF; Galon-Wolfenson Y; Tessier PM; Abramson J; Yarden Y; Fass D; Fleishman SJ
Nat Biomed Eng; 2024 Jan; 8(1):30-44. PubMed ID: 37550425
[TBL] [Abstract][Full Text] [Related]
8. Sagacity in antibody humanization for therapeutics, diagnostics and research purposes: considerations of antibody elements and their roles.
Ling WL; Lua WH; Gan SK
Antib Ther; 2020 Apr; 3(2):71-79. PubMed ID: 33928226
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis.
Park BN; Lee SJ; Roh JH; Lee KH; An YS; Yoon JK
Mol Imaging; 2017; 16():1536012117737399. PubMed ID: 29239276
[TBL] [Abstract][Full Text] [Related]
10. Quantum dots incorporated magnetic nanoparticles for imaging colon carcinoma cells.
Ahmed S; Dong J; Yui M; Kato T; Lee J; Park EY
J Nanobiotechnology; 2013 Aug; 11():28. PubMed ID: 23957878
[TBL] [Abstract][Full Text] [Related]
11. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Gonzales NR; Padlan EA; De Pascalis R; Schuck P; Schlom J; Kashmiri SV
Mol Immunol; 2003 Oct; 40(6):337-49. PubMed ID: 14522015
[TBL] [Abstract][Full Text] [Related]
12. In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
De Pascalis R; Gonzales NR; Padlan EA; Schuck P; Batra SK; Schlom J; Kashmiri SV
Clin Cancer Res; 2003 Nov; 9(15):5521-31. PubMed ID: 14654532
[TBL] [Abstract][Full Text] [Related]
13. SDR grafting--a new approach to antibody humanization.
Kashmiri SV; De Pascalis R; Gonzales NR; Schlom J
Methods; 2005 May; 36(1):25-34. PubMed ID: 15848072
[TBL] [Abstract][Full Text] [Related]
14. Minimizing the immunogenicity of antibodies for clinical application.
Gonzales NR; De Pascalis R; Schlom J; Kashmiri SV
Tumour Biol; 2005; 26(1):31-43. PubMed ID: 15741769
[TBL] [Abstract][Full Text] [Related]
15. Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Kashmiri SV; Iwahashi M; Tamura M; Padlan EA; Milenic DE; Schlom J
Crit Rev Oncol Hematol; 2001 Apr; 38(1):3-16. PubMed ID: 11255077
[TBL] [Abstract][Full Text] [Related]
16. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
